New features include an injection port for small volume additions, a sub-surface fluid port for either addition or removal, and an extra port for the insertion of a third probe. The enhanced version replaces the first-generation Mobius launched in 2009.
Andrew Bulpin, head of services and solutions, Process Solutions, at EMD Millipore, said the enhanced operational and process monitoring capabilities in the new version would enable operations such as perfusion and monitoring of additional cell culture parameters such as carbon dioxide, viable cell density or optical density.
Designed to replace traditional glass benchtop bioreactors, the Mobius CellReady 3L Bioreactor has a standard stirred-tank format for use in development and optimisation of cell culture processes.
According to Millipore, by eliminating time-consuming steps associated with cleaning, assembly, and sterilisation, the Mobius CellReady 3L bioreactor significantly reduces the turnaround time typically associated with glass bioreactors.
Millipore upgrades Mobius CellReady Bioreactor
Offers increased operational flexibility and enhanced process monitoring
You may also like
Trending Articles
You may also like
Manufacturing
The story of an East-West German company | 150 years of Romaco Kilian
Kilian’s story tells of the rise, fall and resurgence of a Berlin company steeped in tradition, which is now based in Cologne. It is the story of the entrepreneur Fritz Kilian, who turned a small locksmith’s workshop in Berlin into a successful company that is still a leading manufacturer of tablet presses today. It is the story of a visionary whose legacy has endured the test of time and continues to this day
Manufacturing
ystral expands India footprint with new Bangalore facility to support Asian markets
German mixing and process technology specialist ystral has opened a new facility in Bangalore, strengthening its Indian operations and laying the groundwork for a regional service hub supporting fast-growing Asian markets
Manufacturing
Why aseptic processing is critical for microsphere drug manufacturing
As microsphere-based drug delivery systems move from niche innovation to commercial reality, manufacturers face growing pressure to guarantee sterility without compromising product integrity. Aseptic processing has become essential to meeting both regulatory expectations and patient safety requirements